Risperdal Lawyers at Bernstein Liebhard LLP Comment on Today’s $2.5 Million Verdict in Gynecomastia Bellwether Trial
New York, New York (PRWEB) February 24, 2015 -- A Pennsylvania jury weighing arguments in an important Risperdal lawsuit (http://www.risperdallawsuit2014.com/) alleging use of the antipsychotic medication can cause boys to develop gynecomastia has today returned a verdict in favor of the plaintiffs, Bernstein Liebhard LLP reports. According to court documents filed in the Philadelphia Court of Common Pleas on February 24th, the jury hit Johnson & Johnson and its Janssen Pharmaceuticals unit with a $2.5 million judgment, after finding that the pharmaceutical companies failed to warn that Risperdal could cause boys to develop female-like breasts. (Case No. A-196444)
“Our Firm is extremely pleased with this verdict, as we are representing numerous clients in Risperdal lawsuits who allegedly developed gynecomastia due to this medication. Like this case, these and other claims pending in the Pennsylvania mass tort accuse the defendants of failing to warn about the potential for Risperdal to cause gynecomastia, and further allege the companies of improperly promoted the drug for off-label use, including for use in children,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.
Risperdal Litigation
According to court documents, the Risperdal verdict was delivered in a litigation that involves nearly 1,300 lawsuits that have been filed on behalf of individuals who allegedly suffered serious side effects, including gynecomastia, due to their use of the medication. (In Re: Risperdal Litigation, Case Number 100300296) Specifically, this case had been filed by the parents of a severely autistic man who was prescribed the drug as a boy in 2002, which the complaint notes was four years before the US. Food & Drug Administration (FDA) had approved its use in children.
Bernstein Liebhard LLP notes that this was the first in the proceeding to involve Risperdal and gynecomastia, and sought compensatory damages for disfigurement and emotional distress suffered by the young man after he developed female-like breasts that grew to a size 44 DD. Court documents indicate that the plaintiffs were prohibited from seeking punitive damages by an earlier court ruling.
“Consolidated litigations like the Risperdal mass tort are intended to allow a large number of claims involving similar allegations of fact to move more efficiently through the court system. As a bellwether trial, this outcome is good news for plaintiffs, as the proceeding was intended to provide insight into possible jury rulings in similar gynecomastia cases involving Risperdal,” says Bernstein Liebhard LLP.
Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author
Sandy A. Liebhard, Risperdal Gynecomastia Lawsuit Center, http://www.risperdallawsuit2014.com/, +1 800-511-5092, [email protected]
Share this article